Fapon Biotech Introduces World’s First COVID-19 Antibodies for Antigen Lateral Flow Testing in Differentiating Variant B.1.1.7 and Wild-Type Virus

Fapon Biotech Inc. (Guangdong, China) introduced the world’s first COVID-19 antibodies for antigen lateral flow testing in differentiating variant B.1.1.7 and wild-type virus at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

This year more than 35,000 industry leaders and professionals came together at the Georgia World Congress Center in Atlanta for AACC 2021. Fapon provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as reagent solutions and innovative open instrument platforms.

At AACC 2021, Fapon introduced pioneering COVID-19 antibodies for antigen lateral flow testing to detect and differentiate COVID-19 and the most notable variant B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) in human samples. Variant strain surveillance is vital for COVID-19 control. Variants such as B.1.1.7 that causes 40-70% higher transmissibility and false-negative results on some PCR tests had drawn concerns and investigation from scientists and healthcare authorities like WHO, FDA and others.

The innovative COVID-19 Variant B.1.1.7 POCT Solution consists of a monoclonal antibody pair to differentiate the SARS-CoV-2 wild-type strain and the B.1.1.7 variant strain N protein. The antibody pair uses two different antibodies for immunoassay of test samples. These antibody pairs can detect B.1.1.7 and B.1.351 variants while having a consistent reaction to the wild-type virus. With the advantages of rapidity, low cost and high efficiency, this product can ensure the rapid and accurate detection of the B.1.1.7 variant strain.

Fapon also showcased its One-Stop Solution for COVID-19 RT-PCR Test that provides the comprehensive reagents, components, materials required to simplify collection, transport, storage and detection of SARS-CoV-2. The solution allows biospecimens to be taken from the collection sites and transported to the hospitals and reference labs where viral RNA is extracted and detected by RT-PCR assays. Also on display at AACC 2021 was Fapon’s COVID-19 NAb Test Solution that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification.

In addition, Fapon highlighted its COVID-19 NAb (neutralizing antibody) Test Solution for Latex-Enhanced Immunoturbidimetry that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification. Fapon displayed its COVID-19 IgM & IgG Quality Control at the event. Fapon’s Anti-SARS-CoV-2 fully human RBD monoclonal antibody and N protein humanized monoclonal antibody outperform positive specimens by exhibiting higher stability, specificity and affinity. They are safe to handle with non-infectious, providing a valuable tool to reagent development, validation, and production.

Fapon also demonstrated the Shine i1000 Fully Automated CLIA Analyzer which has a throughput of up to 120 tests per hour and provides the first result in less than 15 minutes. It combines incubation, washing and detection in an all-in-one innovative design and its small size with a weight of less than 38 kg makes it ideal for different settings.

Related Links:
Fapon Biotech Inc.

Visit expo >

Gold Member

Flocked Fiber Swabs

Puritan® Patented HydraFlock®

New

Gold Member

Antipsychotic TDM Assays

Saladax Antipsychotic Assays

New

Carcinoembryonic Antigen Test

CEA Test

New

Microplates

Eppendorf Microplates